SCARB1 and ischemia: Furthermore, the administration of HDL at reperfusion in the presence of SR-BI blocking antibody significantly (P < 0.05) increased DPmax, cardiac contractility (+dP/dt and –dP/dt) and CF (Figures 5A,C–E) and significantly (P < 0.05) reduced LVEDP and CVR relative to ischemia and relative to untreated controls in WKY (Figures 5B,F).